PMV Pharmaceuticals, Inc. - Common Stock, $0.00001 par value per share (PMVP)

CUSIP: 69353Y103

Q1 2024 13F Holders as of 31 Mar 2024

Holder snapshot 7 signals
Share change
-3,729,529
Put/Call ratio
32%
SEC-reported price per share
$1.70
Number of holders
96
Value change
-$11,853,919
Number of buys
48
Open additional details 1 more signal available
Number of sells
39
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
76,540,071

Security key

69353Y103

Report period

Q1 2024

Institutions

96

Top holders

10

Ownership snapshot

Top reported holders of PMVP - PMV Pharmaceuticals, Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
INTERWEST PARTNERS X LP
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
0/15
Latest evidence
31 Dec 2023
3/4/5 13F Highest disclosed value: $20,073,402 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC has the largest disclosed position value at $20.07M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.
Disclosed position value Top 5
INTERWEST PARTNERS X LP $10.04M
Euclidean Capital LLC $8.15M
ORBIMED ADVISORS LLC $20.07M
JPMORGAN CHASE & CO $12.18M
BlackRock Finance, Inc. $10.01M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
INTERWEST PARTNERS X LP
3/4/5
10%+ Owner
—
denominator unverified
$10,040,531
4,502,480 shares
— 13 Jul 2021
Euclidean Capital LLC
13F 3/4/5
Company · 10%+ Owner
—
denominator unverified
$8,145,693
2,627,643 shares
— 31 Dec 2023
Peter A. Thompson
3/4/5
Director, 10%+ Owner
—
denominator unverified
—
16,333 shares
— 02 Jun 2021
ORBIMED ADVISORS LLC
13F
Company
13F
—
denominator unverified
$20,073,402
6,475,291 shares
— 31 Dec 2023
JPMORGAN CHASE & CO
13F
Company
13F
—
denominator unverified
$12,184,054
3,930,340 shares
— 31 Dec 2023
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$10,012,371
3,229,797 shares
— 31 Dec 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
96
Shares
42,725,320
Rows available
96
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q3 2025 Across Filers

Q3 2025 holders
63
Q1 2024 holders
96
Holder diff
33
Investor Q3 2025 Shares Q1 2024 Shares Share Diff Share Chg % Q3 2025 value Q1 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .